| V80402 | |
|
|
|
| 詢價 | |
|
|
|
|
|
|
| 聯系我們 | |
The
new SARS-CoV-2 variant Omicron (B.1.1.529) was first identified in South Africa
and classified as a variant of concern (VOC). Following the quick rise of the Delta
variant, Omicron’s emergence is concern of scientists due to the impressive
number of mutations within the Spike protein (~ 30 mutations). The increased
number of mutations in Spike’s receptor-binding domain (RBD) may affect this
variant interaction with the ACE2 or neutralizing antibodies. This product is
intended for the calibration of SARS-CoV-2 (Omicron) neutralizing antibodies in
the materials or samples. It can be used in the assessment and development of
assays for the detection and quantitation of SARS-CoV-2 (Omicron) neutralizing
antibodies. |
SARS-CoV-2 (Omicron) Neutralizing Antibody Standard
| Specificity |
The
product is specific for SARS-CoV-2 RBD domain |
| Purification |
Protein
A/G affinity column |
| Formulation |
50
mM Na-citrate, 150 mM NaCl, pH 7.0, containing 0.03% ProClin 300. |
| Storage |
The unopened product
is stable up to the stated expiration date when stored at -25°C~-15°C. The opened product is stable for
1 month from the date of opening when stored at 2°C - 8°C. Avoid repeated freezing and thawing cycles. |
